HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde

Protagonist Therapeutics-partnered Icotyde has the potential to become one of Johnson & Johnson's "largest products ever," CEO Joaquin Duato said on the company's first-quarter earnings conference call.

By FiercePharma · Apr 17, 2026 · via FiercePharma
J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde

Image: FiercePharma

Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Big Pharma’s M&A Jag Freezes Biotech IPO Window
MoneyBriefing
Big Pharma’s M&A Jag Freezes Biotech IPO Window
Seven pharma takeovers over $1B each in late March, totaling $29B, may have sidelined would‑be biotech IPOs af…
Apr 17, 2026
Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
MoneyFierceBiotech ↗
Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pan…
Apr 17, 2026
Abbott lowers EPS guidance on Exact Sciences buy as shares slide
MoneyFierceBiotech ↗
Abbott lowers EPS guidance on Exact Sciences buy as shares slide
Abbott's first-quarter numbers reflect is operational complexity.…
Apr 17, 2026